SCHEMBL6123263

SCHEMBL6123263

CCCCCOC(=O)C(CN(C)C)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
ALOX5 P09917 2/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
CHRM1 P11229 1/20 0.46
PRKCA P17252 2/20 0.46
PRKCD Q05655 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
EGFR P00533 2/20 0.46
ALDH1A1 P00352 1/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6123338 0.99 LMNA (0.48) LMNAALOX5MMP9MMP8MMP13
SCHEMBL1070343 0.98 ALOX5 (0.48) LMNAALOX5CHRM1PRKCAPRKCD
SCHEMBL1071486 0.92 ALOX5 (0.49) LMNAALOX5CHRM1PRKCAPRKCD
SCHEMBL1069511 0.87 LMNA (0.60) LMNAALOX5PRKCAPRKCDL3MBTL1
SCHEMBL1069341 0.83 LTA4H (0.53) ALOX5EGFR
SCHEMBL6122799 0.82 PRKCA (0.53) ALOX5PRKCAPRKCDEGFR
SCHEMBL1070256 0.81 ALOX5 (0.53) LMNAALOX5L3MBTL1EGFR
SCHEMBL1081453 0.81 EGFR (0.48) ALOX5PRKCAPRKCDEGFR
SCHEMBL1070232 0.81 ALOX5 (0.50) LMNAALOX5L3MBTL1EGFRALDH1A1
SCHEMBL6123064 0.81 PRKCA (0.51) ALOX5PRKCAPRKCDEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150183722-A1 Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein CIPLA LIMITED (IN) 2015-07-02 US disclosed
US-9012689-B2 Process for the preparation of O-desmethyl venlafaxine and intermediate for use therein CIPLA LIMITED (IN) 2015-04-21 US disclosed
US-20120157544-A1 Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein CIPLA LIMITED (IN) 2012-06-21 US disclosed
EP-2454228-A2 PROCESS FOR THE PREPARATION OF O-DESMETHYL VENLAFAXINE AND INTERMEDIATE FOR USE THEREIN CIPLA LIMITED (IN) 2012-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150183722-A1 Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein SLC6A2, SLC6A3, MAOA LMNA 1856/4885ALOX5 1190/4885MMP9 1353/4885
US-20120157544-A1 Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein SLC6A2, SLC6A3, MAOA LMNA 1856/4885ALOX5 1190/4885MMP9 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.